Drugs / Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06063057 | Sep 2023 → Dec 2025 | hand, foot and mouth disease, herpangina | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06734832 | Dec 2024 → Nov 2025 overdue | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06063057 ↗ |
| Modality | Vaccine | “inactivated enterovirus vaccine (Vero cell) developed by Sinovac” NCT06063057 ↗ |
| Route | Intramuscular | “complete the full vaccination through intramuscular injection on the anterolateral thigh” NCT06734832 ↗ |